Jie Wang
YOU?
Author Swipe
View article: Study of the blood–brain barrier-penetrating KRAS G12C inhibitor JMKX1899 in KRAS G12C-mutated NSCLC with brain metastases
Study of the blood–brain barrier-penetrating KRAS G12C inhibitor JMKX1899 in KRAS G12C-mutated NSCLC with brain metastases Open
View article: Regulatory effects of row spacing on plant-soil feedbacks in an oat-forage pea intercropping system: a two-year, dual-location study
Regulatory effects of row spacing on plant-soil feedbacks in an oat-forage pea intercropping system: a two-year, dual-location study Open
View article: MiroThinker: Pushing the Performance Boundaries of Open-Source Research Agents via Model, Context, and Interactive Scaling
MiroThinker: Pushing the Performance Boundaries of Open-Source Research Agents via Model, Context, and Interactive Scaling Open
We present MiroThinker v1.0, an open-source research agent designed to advance tool-augmented reasoning and information-seeking capabilities. Unlike previous agents that only scale up model size or context length, MiroThinker explores inte…
View article: Long-term outcomes and clinical features of stage III non-small-cell lung cancer harboring ALK rearrangements: a multicenter retrospective study of 176 patients✰
Long-term outcomes and clinical features of stage III non-small-cell lung cancer harboring ALK rearrangements: a multicenter retrospective study of 176 patients✰ Open
View article: Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies
Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies Open
Malignant mesothelioma (MM) is an aggressive and currently incurable cancer with limited therapeutic options. Due to the high expression of mesothelin in this cancer, anti‐PD‐1 nanobody‐armored mesothelin‐targeting CAR‐T (NAC‐T) cells are …
View article: Long-term outcomes of postoperative radiotherapy for patients with pIIIA-N2 non-small-cell lung cancer after complete resection and adjuvant chemotherapy (PORT-C): a single-centre, randomized, phase 3 trial
Long-term outcomes of postoperative radiotherapy for patients with pIIIA-N2 non-small-cell lung cancer after complete resection and adjuvant chemotherapy (PORT-C): a single-centre, randomized, phase 3 trial Open
View article: First-Line Tislelizumab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: PD-L1 ≥ 50% Subgroup Analysis from the RATIONALE-304 Trial
First-Line Tislelizumab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: PD-L1 ≥ 50% Subgroup Analysis from the RATIONALE-304 Trial Open
Clinical Trials.gov NCT03663205.
View article: Burden of chemotherapy-induced myelosuppression (CIM) in Chinese patients with extensive-stage small cell lung cancer (ES-SCLC): A retrospective real-world study
Burden of chemotherapy-induced myelosuppression (CIM) in Chinese patients with extensive-stage small cell lung cancer (ES-SCLC): A retrospective real-world study Open
View article: Dissecting the genetic architecture of yield-related traits by QTL mapping in maize
Dissecting the genetic architecture of yield-related traits by QTL mapping in maize Open
Introduction Maize is a cornerstone of global agriculture, essential for ensuring food security, driving economic development, and meeting growing food demands. Yet, how to achieve optimal yield remains a multifaceted challenge influenced …
View article: Regulatory effects of row spacing on plant-soil feedbacks in an oat–forage pea intercropping system: a two-year, dual-location study
Regulatory effects of row spacing on plant-soil feedbacks in an oat–forage pea intercropping system: a two-year, dual-location study Open
To clarify the effects of row spacing on forage yield, quality, and soil function in an oat–forage pea intercropping system in the high-altitude Qinghai–Tibet region, this study systematically evaluated the combined effects of row spacing …
View article: Supplementary Figure S5 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
Supplementary Figure S5 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer Open
Supplementary Figure 5. The exploratory analysis of PFS according to HVEM and PD-L1 expression.
View article: Supplementary Table S3 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
Supplementary Table S3 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer Open
Supplementary Table 3. Treatment-related treatment-emergent adverse events occurring in ≥5% of all patients.
View article: Supplementary Table S2 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
Supplementary Table S2 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer Open
Supplementary Table 2. Representativeness of study participants.
View article: Supplementary Figure S2 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
Supplementary Figure S2 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer Open
Supplementary Figure 2. Kaplan-Meier estimation of DOR.
View article: Supplementary Table S1 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
Supplementary Table S1 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer Open
Supplementary Table 1. Subsequent systemic antitumor therapy.
View article: Data from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
Data from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer Open
Purpose:Tifcemalimab is a recombinant humanized IgG4k monoclonal antibody targeting B- and T-lymphocyte attenuator. Co-blockade of B- and T-lymphocyte attenuator and programmed death-1 pathways improved outcomes in nonclinical models. This…
View article: Supplementary Figure S1 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
Supplementary Figure S1 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer Open
Supplementary Figure 1. Kaplan-Meier estimation of progression-free survival in (A) squamous non-small cell lung cancer (NSCLC), (B) adenocarcinoma NSCLC, overall survival in (C) squamous NSCLC and (D) adenocarcinoma NSCLC.
View article: Supplementary Figure S4 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
Supplementary Figure S4 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer Open
Supplementary Figure 4. Representative immunohistochemistry staining.
View article: Supplementary Figure S3 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
Supplementary Figure S3 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer Open
Supplementary Figure 3. Kaplan-Meier estimation of PFS and OS in SCLC with immunotherapy or not.
View article: Supplementary Table S4 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
Supplementary Table S4 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer Open
Supplementary Table 4. Immune-related treatment-emergent adverse events of any grade and grade 3 or higher.
View article: Effects of arabinoxylan on BDNF/TrkB/p-CREB signaling pathway in the prefrontal cortex and intestinal microbiome in post-stroke depressed rats
Effects of arabinoxylan on BDNF/TrkB/p-CREB signaling pathway in the prefrontal cortex and intestinal microbiome in post-stroke depressed rats Open
View article: Potassium Fulvate Alleviates Salinity and Boosts Oat Productivity by Modifying Soil Properties and Rhizosphere Microbial Communities in the Saline–Alkali Soils of the Qaidam Basin
Potassium Fulvate Alleviates Salinity and Boosts Oat Productivity by Modifying Soil Properties and Rhizosphere Microbial Communities in the Saline–Alkali Soils of the Qaidam Basin Open
Soil salinization severely limits global agricultural sustainability, particularly across the saline–alkaline landscapes of the Qinghai–Tibet Plateau. We examined how potassium fulvate (PF) modulates oat (Avena sativa L.) performance, soil…
View article: [Ferroptosis-related long non-coding RNA to predict the clinical outcome of non-small cell lung cancer after radiotherapy].
[Ferroptosis-related long non-coding RNA to predict the clinical outcome of non-small cell lung cancer after radiotherapy]. Open
The risk model developed in this study can independently predict the prognosis of NSCLC patients after radiotherapy. This model provides a solid basis for understanding the role of ferroptosis-related lncRNA in the prognosis of NSCLC patie…
View article: Rapid diagnosis of disseminated <i>Mycobacterium avium</i> complex infection mimicking metastatic malignancy using metagenomic next-generation sequencing
Rapid diagnosis of disseminated <i>Mycobacterium avium</i> complex infection mimicking metastatic malignancy using metagenomic next-generation sequencing Open
Disseminated non-tuberculous mycobacteria (NTM) disease, which is mainly found in immunocompromised individuals, is a rare and severe infection whose diagnosis poses a challenge to clinicians. We present a patient with disseminated NTM inf…
View article: Correlation analysis of pharmacokinetic parameters of docetaxel AUC and adverse reactions in breast cancer patients
Correlation analysis of pharmacokinetic parameters of docetaxel AUC and adverse reactions in breast cancer patients Open
Background Docetaxel is commonly used in breast cancer chemotherapy. The previous drug dose is generally calculated based on body surface area (BSA). However, the metabolism varies greatly among different patients. Docetaxel therapeutic dr…
View article: Developing a quality evaluation indicator system for lung cancer diagnosis and treatment: a modified delphi method study
Developing a quality evaluation indicator system for lung cancer diagnosis and treatment: a modified delphi method study Open
Objective: To establish a quality evaluation index system for the diagnosis and treatment of lung cancer. Method: The Donabedian health assessment model and Delphi method were used to construct an indicator system, and the Analytic Hierarc…
View article: Socioeconomic Status, Modifiable Factors, and Risk of Microvascular Complications in Individuals With Type 2 Diabetes: A Cohort Study From the <scp>UK</scp> Biobank
Socioeconomic Status, Modifiable Factors, and Risk of Microvascular Complications in Individuals With Type 2 Diabetes: A Cohort Study From the <span>UK</span> Biobank Open
Background To investigate whether lower socioeconomic status (SES) was associated with an increased risk of diabetic microvascular complications and to analyze the potential mediating role of several modifiable factors. Methods The study i…
View article: Alzheimer’s disease diagnosis among dementia patients via blood biomarker measurement based on the AT(N) system
Alzheimer’s disease diagnosis among dementia patients via blood biomarker measurement based on the AT(N) system Open
View article: Author Correction: Assessment of human leukocyte antigen-based neoantigen presentation to determine pan-cancer response to immunotherapy
Author Correction: Assessment of human leukocyte antigen-based neoantigen presentation to determine pan-cancer response to immunotherapy Open
View article: Oat and Forage Pea Mixed Sowing Improves Soil Chemical Fertility and Fresh and Dry Mass Yield in Light Saline–Alkali Land: Preliminary Results
Oat and Forage Pea Mixed Sowing Improves Soil Chemical Fertility and Fresh and Dry Mass Yield in Light Saline–Alkali Land: Preliminary Results Open
Saline–alkali land is widely distributed worldwide, and poses significant challenges to agricultural productivity and ecological restoration, particularly in the Qaidam Basin. This study investigates the effects of intercropping and mixed …